KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $1.3 million.

  • Adaptive Biotechnologies' Change in Inventory rose 17937.54% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year increase of 5987.93%. This contributed to the annual value of -$5.4 million for FY2024, which is 28928.82% down from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Change in Inventory is $1.3 million, which was up 17937.54% from -$95000.0 recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Change in Inventory peaked at $6.6 million during Q1 2023, and registered a low of -$4.0 million during Q4 2023.
  • Moreover, its 5-year median value for Change in Inventory was -$65000.0 (2023), whereas its average is $149315.8.
  • In the last 5 years, Adaptive Biotechnologies' Change in Inventory skyrocketed by 651111.11% in 2021 and then plummeted by 72161.17% in 2024.
  • Adaptive Biotechnologies' Change in Inventory (Quarter) stood at $1.0 million in 2021, then tumbled by 393.51% to -$3.0 million in 2022, then tumbled by 31.3% to -$4.0 million in 2023, then grew by 14.96% to -$3.4 million in 2024, then skyrocketed by 139.83% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$95000.0 for Q2 2025, and -$264000.0 during Q1 2025.